Gerstein, H. Et Al. 2021. Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. NEW ENGLAND JOURNAL OF MEDICINE , vol.385, no.10 , 896-907.

Gerstein, H., Sattar, N., Rosenstock, J., Ramasundarahettige, C., Pratley, R., Lopes, R., ... Lam, C.(2021). Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. NEW ENGLAND JOURNAL OF MEDICINE , vol.385, no.10, 896-907.

Gerstein, Hc Et Al. "Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes," NEW ENGLAND JOURNAL OF MEDICINE , vol.385, no.10, 896-907, 2021

Gerstein, Hc Et Al. "Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes." NEW ENGLAND JOURNAL OF MEDICINE , vol.385, no.10, pp.896-907, 2021

Gerstein, H. Et Al. (2021) . "Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes." NEW ENGLAND JOURNAL OF MEDICINE , vol.385, no.10, pp.896-907.

@article{article, author={Hc Gerstein Et Al. }, title={Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes}, journal={NEW ENGLAND JOURNAL OF MEDICINE}, year=2021, pages={896-907} }